MicroVention Celebrates 25 Years in Neuroendovascular Technologies that Improve Patient Lives

MicroVention, Inc., a global neurovascular company and a wholly owned subsidiary of Terumo Corporation, celebrates its 25-year anniversary on September 29, 2022. Founded in 1997 by a handful of Associates in a small facility in Southern California, MicroVention is now a worldwide community with over 3,000 Associates and distributors worldwide, operating in over 70 countries with offices across the United States, Europe, Asia, and Costa Rica.

MicroVention has been focused on developing and marketing medical devices that improve patient lives through the treatment of strokes and aneurysms using our innovative products. In 2006, MicroVention was acquired by the Japan-based Terumo Corporation. Terumo provided the support for MicroVention to continue the culture of innovation and an entrepreneurial spirit.

MicroVention has launched over 30 products and has expanded beyond cerebral aneurysms to include treatment for ischemic stroke, carotid artery disease, and neurovascular malformations.

On MicroVention’s 25th anniversary, celebrations will occur across the globe that focus on its patients, product innovation, and its people – its Associates. The capstone of the anniversary celebration will include Patient’s Day. Dr. Timothy White, a Neurosurgery Chief Resident and Endovascular Fellow at the Zucker School of Medicine at Hofstra Northwell, will provide an overview of a patient that was treated with MicroVention products. Likewise, the patient will share her story of the positive impact and improvement of her life from being treated with multiple MicroVention products.

Also, as part of the anniversary ceremonies, MicroVention will add to a time capsule that was built for the company’s 20-year anniversary in 2017 that was filled with various artifacts from the past 20 years of the company’s history. The time capsule will be sealed and reopened in 2047 as a way of celebrating what the next 25 years may bring to the industry and company.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version